Text Size: A- A+ Facebook Twitter LinkedIn YouTube

Breaking News

Pledge the Gift of Life

Each year, the lives of thousands of people across the country are saved because someone made the choice to become an organ donor. In April, Allegheny Health Network is honored to celebrate National Donate Life Month and pay tribute to all of those who have bestowed the precious gift of life to another through organ donation. Visit AHNdonate.org to learn more and register to be an organ donor.



Format: 04/24/2014
Format: 04/24/2014


CBS Early Show: Possible Big Advance Against Brain Cancer

Tuesday, May 11th, 2010

Brain cancer is one of the most deadly of cancers but a new treatment procedure targeting tumors may offer new hope for patients.

Dr. Jennifer Ashton reports that the experimental procedure "could become a major breakthrough in the treatment of brain cancer."

Ashton went to Pittsburgh's Allegheny General Hospital, one of four in the United States conducting trials of the use of a fluorescent compound called 5-aminolevulinic acid (ALA) in patients diagnosed with a glioma, the most common form of primary brain tumor.

Gliomas hit some 10-12,000 Americans each year and, says the hospital, "vary in severity. High-grade gliomas … are rapidly progressive and fatal malignant tumors. Low-grade gliomas are more treatable, but also pose a risk of becoming cancerous overtime."

With aggressive treatment, Ashton points out, the average life expectancy for someone with a glioma is only 13 months.

The compound, Ashton explains, is given by mouth, then ultraviolet light is used to illuminate brain cancer cells, enabling surgeons to see them better and remove a bigger portion of them, without endangering surrounding healthy tissue.

Ashton visited with John and Betty Volna. He had the surgery and is doing well.

The director of the hospital's Neurosurgical Oncology unit, Dr. Matthew Quigley, says, "It turns out that the stuff that looks perfectly normal under the surgical microscope is tumor. We didn't know that until we had the drug."

Ashton says the other three U.S. hospitals using the procedure are Case Western, in Cleveland, Lutheran Advocate, outside Chicago, and Dartmouth Hitchcock, in New Hampshire.

Each has to petition the Food and Drug Administration through a grant-type process to allow it to conduct the clinical trial with 50 patients, and document the success rate.

This began in Germany, Ashton adds, where use of the drug is standard in glioblastoma surgery. It crossed the Atlantic when a neurosurgeon read about it in a medical journal. In terms of changing the standards in the U.S., the hope is that if enough of the neurosurgical community throws its support behind it over the next few years, they can take comprehensive research to the FDA.

There's no data to support that it might help battle other forms of cancer, Ashton says, but the neurosurgeons she spoke with said they think there's potential for colon cancer surgery, because of the similar nature of the tissue and how it would react to the drug and ultraviolet light.

West Penn Allegheny Health System
Tell us who you are:

What areas do you use on our website?*
(select more than one if it applies)

Did you find what you were looking for?

Would you refer others to our website?

Can we contact you for future questions?

CAPTCHA math question:* 7 + 4 =

Thank you for completing the West Penn Allegheny Health System website survey.
We value your feedback and comments.